1. Home
  2. LQDA vs WLKP Comparison

LQDA vs WLKP Comparison

Compare LQDA & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • WLKP
  • Stock Information
  • Founded
  • LQDA 2004
  • WLKP 2014
  • Country
  • LQDA United States
  • WLKP United States
  • Employees
  • LQDA N/A
  • WLKP N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • WLKP Major Chemicals
  • Sector
  • LQDA Health Care
  • WLKP Industrials
  • Exchange
  • LQDA Nasdaq
  • WLKP Nasdaq
  • Market Cap
  • LQDA 1.2B
  • WLKP 789.3M
  • IPO Year
  • LQDA 2018
  • WLKP 2014
  • Fundamental
  • Price
  • LQDA $14.51
  • WLKP $22.13
  • Analyst Decision
  • LQDA Strong Buy
  • WLKP
  • Analyst Count
  • LQDA 9
  • WLKP 0
  • Target Price
  • LQDA $27.67
  • WLKP N/A
  • AVG Volume (30 Days)
  • LQDA 2.0M
  • WLKP 31.7K
  • Earning Date
  • LQDA 08-06-2025
  • WLKP 08-05-2025
  • Dividend Yield
  • LQDA N/A
  • WLKP 8.52%
  • EPS Growth
  • LQDA N/A
  • WLKP N/A
  • EPS
  • LQDA N/A
  • WLKP 1.49
  • Revenue
  • LQDA $14,144,000.00
  • WLKP $1,088,852,000.00
  • Revenue This Year
  • LQDA $189.27
  • WLKP $8.90
  • Revenue Next Year
  • LQDA $402.79
  • WLKP $6.87
  • P/E Ratio
  • LQDA N/A
  • WLKP $14.85
  • Revenue Growth
  • LQDA N/A
  • WLKP N/A
  • 52 Week Low
  • LQDA $8.26
  • WLKP $21.19
  • 52 Week High
  • LQDA $19.41
  • WLKP $25.04
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 55.41
  • WLKP 50.62
  • Support Level
  • LQDA $11.86
  • WLKP $22.14
  • Resistance Level
  • LQDA $14.99
  • WLKP $22.60
  • Average True Range (ATR)
  • LQDA 0.72
  • WLKP 0.29
  • MACD
  • LQDA 0.30
  • WLKP 0.03
  • Stochastic Oscillator
  • LQDA 84.71
  • WLKP 66.57

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

Share on Social Networks: